Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd is positioned for significant growth, supported by a strong preference for its lead product, Brukinsa, over competing BTK inhibitors, with projected peak sales reaching approximately $7.1 billion. The company’s innovative therapeutic portfolio, including the advanced sonrotoclax, is expected to demonstrate superior efficacy and safety, potentially outperforming existing treatments like venetoclax and contributing an estimated $3.4 billion in peak sales. With strategic physician outreach and favorable market perceptions, BeOne Medicines aims for over 40% year-over-year growth in 2025, ultimately targeting profitable operations and positive free cash flow by 2025.

Bears say

BeOne Medicines Ltd faces a challenging outlook due to several key financial risks. The potential for slower-than-expected uptake of commercial products, combined with setbacks in pipeline development and regulatory hurdles, raises significant concerns about the company's ability to maintain a competitive position and achieve projected revenues. Additionally, high cash burn rates, geopolitical perceptions affecting market sentiment, and the crowded landscape of hematologic oncology could further destabilize the company's financial performance and prospects for growth.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $380.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $380.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.